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Abstract Migraine is a common neurological disorder
and epidemiological studies have documented its high
social and economic impact. Unfortunately, preventive
treatment is often insufﬁcient to substantially reduce
migraine frequency or it is not well tolerated. Antiepileptic
drugs are increasingly used in migraine prevention. How-
ever, data on efﬁcacy and tolerability of pregabalin in
patients with migraine are still lacking. Our aim was to
evaluate efﬁcacy and tolerability of pregabalin in patients
with migraine. We recruited 47 patients who started pre-
gabalin at 75 mg/day, which was titrated to 300 mg/day as
tolerated. A total of six patients (13%) reported one or
more side effects during the intake of pregabalin; however,
three of them discontinued pregabalin, because side effects
were intolerable and persistent. Statistically signiﬁcant
reduction in migraine frequency compared to baseline
(p\0.001) was evident after 1 and 3 months of treatment.
A greater frequency reduction was observed in those
patients who increased the dosage within the ﬁrst month of
therapy. Our data suggest that pregabalin may be well
tolerated and may represent an alternative preventive
treatment in migraneurs. Limitations of the present study
were a small sample size and an uncontrolled, open-label
design; further randomized case–control studies are war-
ranted to conﬁrm our ﬁndings.
Keywords Migraine  Pregabalin 
Prophylaxis therapy  Disability
Introduction
Migraine is a common neurological disorder that affects
approximately 12% of adult population [1]. Epidemiolog-
ical studies have documented a high impact and the pro-
found effect that the disorder can have on an individual’s
quality of life [2]. Although migraine is a highly prevalent
and disabling condition, it is underdiagnosed and under-
treated [3, 4]. Recent advances have been made in the
management of migraine, but pharmacologic treatment
options are still far from optimum, leaving many patients
without pain-free treatments or with unpleasant side effects
[5, 6]. Nowadays, antiepileptic drugs (AEDs) are increas-
ingly used in migraine treatment [7, 8]; in general, these
agents are considered both effective in reducing attack
frequency and reasonably well tolerated, although few
robust trials are available for AEDs other than divalproex
sodium and topiramate [9, 10]. These are favored by Level
1 evidence and clinical experiences as ﬁrst-line preventive
drugs for migraine [10, 11]. Recently, other different AEDs
such as pregabalin are emerging in the prophylaxis of
migraine [12, 13].
Pregabalin is currently recommended for the treatment
of partial seizures, pain associated with post-herpetic
neuralgia, diabetic neuropathy, ﬁbromyalgia and spinal
cord damage, as well as in the treatment of generalized
anxiety disorder [14–16]. Pregabalin, through binding to
the alpha2-delta subunits of hyperexcited, voltage-gated
calcium channels, reduces the calcium inﬂux at neurons
terminals and subsequently reduces the synaptic release of
several excitatory neurotransmitters such as glutamate,
R. Pizzolato  V. Villani  A. Ciuffoli  G. Sette
Neurological Headache Centre, S. Andrea Hospital,
Sapienza University, Rome, Italy
V. Villani (&)  L. Prosperini  A. Ciuffoli
Department of Neurology and Psychiatry, Headache Centre,
S. Andrea Hospital, Sapienza University,
Via di Grottarossa, 1035, 00189 Rome, Italy
e-mail: veronicavillani@hotmail.it
123
J Headache Pain (2011) 12:521–525
DOI 10.1007/s10194-011-0338-0noradrenaline and substance P. Therefore, pregabalin
restores the hyperexcited calcium channels to a normal
state [17]. Pregabalin mechanism of action is coherent with
the available data concerning glutamatergic mechanism in
migraine physiopathology.
The primary aim of this study was to evaluate the
effectiveness of pregabalin in reducing migraine fre-
quency; secondarily, we aimed to investigate the safety and
the tolerability of pregabalin.
Methods
Outpatients with a diagnosis of migraine according to
International Headache Criteria (ICHD II) [18], and regu-
larly attending the Neurological Headache Centre of S.
Andrea Hospital in Rome were considered during a period
of 6 months.
Those patients eligible for prophylactic treatment (i.e.,
patients with C4 attacks per month) were asked to partic-
ipate to this independent, uncontrolled, open-label, obser-
vational, prospective study. The exclusion criteria included
an age younger than 18 years, medical or neurological
disorders capable of causing headache, pregnancy, breast-
feeding, and rescue medications overuse. An informed
consent was obtained from each participant.
Following a 6-month period of wash-out after the last
assumption of preventive agents, each eligible patient
started pregabalin on a 75 mg/day dosage, which was
titrated up to a maximum of 300 mg/day with a 75 mg
increase per week, as tolerated.
Patients were allowed to use acute pain medications
during the evaluation period, including triptans, non-ste-
roidal anti-inﬂammatory drugs, and antiemetics, but not
other preventive therapies. They were allowed to take only
15 acute pain medications per months to avoid medication
overuse.
Clinical data and the frequency of migraine (measured
as days with headache per month) were collected for a
3-month period before starting the therapy, and after 1 and
3 months of pregabalin treatment, by means of patient
diaries or during the 1-month scheduled interviews. The
occurrence of side effects or adverse events were also
recorded at ﬁrst and third month of pregabalin intake.
Statistical analysis
To evaluate the efﬁcacy of pregabalin, we performed an
intention-to-treat analysis. All values are expressed as a
mean ± standard deviation (±SD), or interval, as appro-
priate. Statistical differences over time in days with head-
ache per month were analyzed using the univariate analysis
of the variance (ANOVA) for repeated measures. Response
rate in terms of proportion of patients with a 50% fre-
quency reduction was also presented.
All p values less than 0.05 (two-sided) were considered
as signiﬁcant. Statistical analyses were carried out by using
a PC version of the Statistical Package for Social Sciences
16.0 (SPSS, Chicago, IL, USA).
Results
Forty-seven patients (10 males, 37 females) were included
in the present study. The mean age at the study enrolment
was 48.0 ± 15.8 years (interval 20–83 years). According
to the ICHD-II criteria [18], 21 patients (45%) had a
diagnosis of migraine without aura and 26 patients (55%)
had a chronic migraine (i.e., patients with C15 days with
headache per month) without overuse of symptomatic
drugs. Seven (15%) patients (six chronic and one episodic
migraneurs) had a psychiatric comorbidity according to
DSM-IV criteria (three affected by depression, four affec-
ted by anxiety).
Only seven patients (15%) had never used prophylactic
treatment, while forty (85%) tried at least one drug for
migraine prophylaxis (see Table 1) before starting the
pregabalin therapy. The migraine preventive medication
class most commonly used was tricyclic antidepressants
(38 patients, 95%), followed by anticonvulsants (34
patients, 85%), calcium-channel blockers (18 patients,
45%) and b-blockers (10 patients, 25%).
All patients started the pregabalin therapy at a dosage of
75 mg/day. The majority of patients (n = 33) had a dose
increase within the ﬁrst month of therapy: 30 patients
achieved a daily dose of 150 mg, one patient 225 mg, and
two patients 300 mg. These different dosages were
achieved according to the pregabalin tolerability and the
compliance of the patients. The majority of patients did not
reach the maximum daily dosage (300 mg) also because of
the concerns regarding the potential side effects, or satis-
factory response to lower dosages.
Eleven patients (23%) discontinued the pregabalin
therapy after a mean time of 1.2 ± 0.4 months because of
Table 1 Migraine prophylactic drugs used before pregabalin
Medication class Drugs No. of patients %
Antiepileptics Topiramate 20 50
Gabapentin 24 60
Valproic acid 4 10
b-blockers Propanolol 10 25
Calcium-channel blockers Flunarizine 15 37.5
Cinnarizine 4 10
Antidepressants Amitriptyline 38 95
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123lack of effectiveness (seven), occurrence of side effects
(three) and economic reasons (one). No serious adverse
events occurred during the period of observation. A total of
six patients (13%), all with a previous exposure to pro-
phylactic drugs, reported one or more side effects during
the intake of pregabalin; three of them had tolerable and
transient side effects (see also Table 2). There was no
relationship between the patients’dosage of pregabalin, or
the time of titration, and the occurrence of side effects (data
not shown).
A signiﬁcant reduction in frequency (p\0.001) was
observed after 1 and 3 months of treatment compared to
the baseline (-32 and -31%, respectively) (Fig. 1). When
compared to the baseline value, 12 (26%) patients had a
reduction equal or more than 50% in number of days with
headache per month. Overall, 28 patients (60%) had at least
a 1/4 attack frequency decrease (Table 3).
The signiﬁcant reduction of attack frequency per month
was similar (about 33%) between episodic (from 6.8 ± 3.0
to 4.8 ± 3.5) and chronic migraineurs (from 27.6 ± 5.2 to
18.7 ± 9.7).
Furthermore, the level of response to pregabalin was not
inﬂuenced by sex, age, previous use of prophylactic drug,
or comorbid psychiatric disorders (data not shown), but a
greater reduction in days with headache per month was
observed in the 33 patients who reached a daily dose of at
least 150 mg (Fig. 2). We did not observe any signiﬁcant
reduction in migraine frequency at ﬁrst month in patients
receiving a daily dose of 75 mg. On the contrary, patients
treated with a dose C150 mg/day had beneﬁcial effect
even at ﬁrst month, which was sustained at the end of the
third month of therapy.
Discussion
We found a signiﬁcant reduction in mean days with
headache per month when compared to baseline after 1 and
3 months of therapy. Roughly, the one quarter of our study
population had a response rate equal or more than 50% in
terms of reduction of number of days with headache per
month with respect to the baseline values. These ﬁndings
are consistent with the modest, but clinically relevant
improvement in attack frequency observed in another study
of 30 chronic migraine subjects [12].
We observed a more relevant and faster reduction of
attack frequency in patients who reached a daily dose of
150 mg even in the ﬁrst month. On the contrary, when the
titration was slower, we found a delay in achieving a sig-
niﬁcant reduction in attack frequency, which was reached
only at the third month of pregabalin therapy.
Table 2 Side effects reported
by patients treated with
pregabalin (n = 6)
All these six patients had
previous exposure to
prophylactic drugs
Sex Age Diagnosis Comorbid psychiatric
disorders
Maximum
dosage
Side effects
F 51 Migraine without aura N 75 Drowsiness
Blurred vision
F 78 Chronic migraine Y 150 Drowsiness
Confusion
F 51 Chronic migraine N 150 Drowsiness
M 51 Chronic migraine Y 150 Dizziness
F 37 Migraine without aura N 150 Drowsiness
Fatigue
F 59 Chronic migraine N 150 Drowsiness
Abdominal pain
Fig. 1 Mean number of days with headache per month, with relative
95% conﬁdence intervals, at different time point for the whole study
population. p value\0.001 (ANOVA)
Table 3 Reduction in number of days with headache per month
when compared to baseline value
Percentage of reduction Patients, n (%)
C50 12 (26)
49–25 16 (34)
\25 19 (40)
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serious adverse events occurred in our population) and
generally well tolerated. In our sample the dose or titration
of pregabalin did not seem to be related to the occurrence
of side effects, which occurred in only six (13%) patients
assuming B150 mg/day. Calandre et al. [12] reported that
pregabalin is well tolerated, but 33.3% of patients exhibited
dose-dependant side effects, especially after dosage
adjustment; however, only two patients withdrew because
of treatment-related adverse effects.
AEDs such as gabapentin and pregabalin may be better
preventive therapies for old patients than the other thera-
peutic options, because of their low adverse effects on
cardiovascular system and on mood disorders, such as
anxiety and depression, that are very common in elderly.
This explains the mean age range (20–83 years) of the
sample studied higher than that of trials about other pre-
ventive therapies.
Being an observational study, our ﬁndings suffer from
some limitations, including an uncontrolled and open-label
design and the small sample size. Moreover, there was no
evaluation of indirect measures regarding the efﬁcacy of
pregabalin,suchasquantiﬁcationofheadacheseverity,orthe
number of rescue medications intake during the follow-up.
Conclusion
Despite limitations due to a small sample size and an
uncontrolled, open-label design, the present study suggests
that pregabalin may represent an efﬁcacious and safe anti-
migraine agent in both episodic and chronic migraine
patients.
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